niacinamide has been researched along with staurosporine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goekjian, P; Jochum, A; Jung, M; Kunick, C; Marshall, B; Meier, R; Saunders, L; Sippl, W; Trapp, J; Verdin, E | 1 |
| Kameoka, M; Kamiya, T; Kojima, K; Tanaka, Y; Tohno, Y; Yoshihara, K | 1 |
| Hara, Y; Kimura, S; Kobayashi, S; Masuda, Y; Nakaya, H; Saito, T; Takizawa, T | 1 |
| von Mehren, M | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Bui, B; Italiano, A | 1 |
| Ehninger, G; Illmer, T | 1 |
| Aberg, E; Duyster, J; Engh, RA; Peschel, C; Sänger, J; von Bubnoff, N | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Chen, YC; Jeng, ST; Lin, CC; Lin, HH; Lin, JS | 1 |
| Carter, BD; Scheib, JL; Sullivan, CS | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Abd El Razik, HA; Abu-Serie, MM; El-Miligy, MM | 1 |
8 review(s) available for niacinamide and staurosporine
| Article | Year |
|---|---|
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
14 other study(ies) available for niacinamide and staurosporine
| Article | Year |
|---|---|
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
Topics: Acetylation; Adenosine; Binding Sites; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Models, Molecular; Molecular Mimicry; Protein Kinase Inhibitors; Sirtuins; Structure-Activity Relationship; Tubulin | 2006 |
Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked resistance of HL-60 cells to various apoptosis-inducers.
Topics: Adenosine; Alkaloids; Apoptosis; Calcimycin; Camptothecin; Dactinomycin; DNA, Neoplasm; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Enzyme Inhibitors; HL-60 Cells; Humans; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Staurosporine; Teniposide | 1995 |
Endothelin-1 partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells.
Topics: Action Potentials; Adenosine Triphosphate; Alkaloids; Animals; Azepines; Benzopyrans; Cromakalim; Endothelin Receptor Antagonists; Endothelins; Female; Glyburide; Guinea Pigs; Heart; Heart Ventricles; Hypoglycemic Agents; Male; Niacinamide; Nicorandil; Oligopeptides; Papillary Muscles; Potassium Channels; Protein Kinase C; Pyrroles; Staurosporine; Sulfonamides; Vasodilator Agents | 1996 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Topics: Animals; Benzenesulfonates; Cell Line; Drug Resistance; fms-Like Tyrosine Kinase 3; Indoles; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Receptors, Platelet-Derived Growth Factor; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2009 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cyclin G1; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sorafenib; Staurosporine; Up-Regulation | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
MicroR828 regulates lignin and H2O2 accumulation in sweet potato on wounding.
Topics: Acetates; Agrobacterium; Antioxidants; Base Sequence; Calcium; Cyclic ADP-Ribose; Cyclic GMP; Cyclopentanes; Ethylenes; Gene Expression Profiling; Gene Expression Regulation, Plant; Hydrogen Peroxide; Ipomoea batatas; Lignin; MicroRNAs; Molecular Sequence Data; Niacinamide; Nitric Oxide; Okadaic Acid; Oxylipins; Phosphoprotein Phosphatases; Plant Proteins; Plants, Genetically Modified; Propanols; Protein Kinases; RNA, Messenger; Staurosporine; Stress, Mechanical | 2012 |
Jedi-1 and MEGF10 signal engulfment of apoptotic neurons through the tyrosine kinase Syk.
Topics: Amino Acid Motifs; Animals; Apoptosis; Arabidopsis Proteins; Cell Count; Cells, Cultured; Coculture Techniques; Embryo, Mammalian; Enzyme Inhibitors; Female; Ganglia, Spinal; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Immunoprecipitation; Immunoreceptor Tyrosine-Based Activation Motif; Intracellular Signaling Peptides and Proteins; Intramolecular Transferases; Male; Membrane Proteins; Mice; Microglia; Mutagenesis, Site-Directed; Mutation; Neurons; Niacinamide; Phagocytosis; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering; Signal Transduction; Staurosporine; Syk Kinase; Transfection | 2012 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
Topics: Apoptosis; Binding Sites; Caspases; Cell Line, Tumor; Hep G2 Cells; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Piperazine; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Staurosporine; Thiazolidines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |